The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.
Study Type
OBSERVATIONAL
Enrollment
170
Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
Seoul National University Hospital
Seoul, South Korea
RECRUITINGprogression free survival
the index date is the date of treatment with atezolizumab and bevacizumab, and the event is either death or tumor progression of the tumor.
Time frame: the follow up will be continued until June 22th 2025.
Overall survival
the index date is the date of treatment with atezolizumab and bevacizumab, and the event is death.
Time frame: the follow up will be continued until June 22th 2025.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.